Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Latest From Ipsen

Pipeline Watch: Phase III Progress With Avelumab, Ixekizumab And Eravacycline

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Pipeline Watch Approvals

Ipsen CEO To Feed Group's Three Therapeutic Engines Fresh Assets In 2018

CEO David Meek Says Ipsen has more than $1bn for M&A use to expand its product line in oncology, neuroscience and rare diseases.

Business Strategies Commercial

Appointments: Celgene, Merck KGaA, Ipsen, Ablynx, Advicenne, Dragonfly, Ritter And The ABPI

Company personnel changes in the past week include the CEO of Celgene adding to his responsibilities with the role of chairman, a new CIO at Merck KGaA, new CMOs at Ipsen and Dragonfly Therapeutics, and new CSOs at Ablynx and the ABPI. Vice presidents of clinical development have been named at Advicenne and Ritter Pharmaceuticals.

Appointments BioPharmaceutical

Pipeline Watch: Top-Line Data For Reslizumab, Erenumab And Biosimilar Rituximab

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Pipeline Watch Approvals
See All

Company Information

  • Industry
  • Pharmaceuticals
    • OTC, Consumer
    • Specialty Pharmaceuticals
  • Therapeutic Areas
  • Cancer
  • Gastrointestinal
  • Gynecological, Urological
  • Metabolic Disorders
  • Musculoskeletal & Connective Tissue Disorders
  • Neurology, Nervous System
  • Alias(es)
  • Beaufour Ipsen
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • Europe
      • Western Europe
        • France
  • Company Type
  • Midsize European
  • Parent & Subsidiaries
  • Ipsen
  • Senior Management
  • David Meek, CEO
    Claude Bertrand, PhD, EVP, R&D & CSO
    Aymeric Le Chatelier, EVP, Fin.
    Christophe Jean, EVP, Strategy & Bus. Dev.
    Benoit Hennion, EVP, Pres., Primary Care
  • Contact Info
  • Ipsen
    Phone: (33) 1 58 33 50 00
    65 quai George Gorse
    Boulogne-Billancourt, 92100
    France
Advertisement
Advertisement
UsernamePublicRestriction

Register